NLRP3 and type 2 diabetes mellitus: The above studies indicate that metformin has the potential to inhibit NLRP3 inflammasome activity in chronic diseases (such as T2DM), while it may promote the activity of inflammasomes in acute diseases (such as bacterial infections).